阿卡迪亚制药公司（纳斯达克股票代码：ACAD）濒临收支平衡
ACADIAPharmaceuticalsInc.(NASDAQ:ACAD)ispossiblyapproachingamajorachievementinitsbusiness,sowewouldliketoshinesomelightonthecompany.ACADIAPharmaceuticalsInc.,abiopharmaceuticalcompany,focusesonthedevelopmentandcommercializationinnovativemedicinesthataddressunmetmedicalneedsincentralnervoussystem(CNS)disordersandrarediseasesintheUnitedStates.On31December2023,theUS$2.9bmarket-capcompanypostedalossofUS$61mforitsmostrecentfinancialyear.ManyinvestorsarewonderingabouttherateatwhichACADIAPharmaceuticalswillturnaprofit,withthebigquestionbeing"whenwillthecompanybreakeven?"Belowwewillprovideahigh-levelsummaryoftheindustryanalysts'expectationsforthecompany.
Accordingtothe21industryanalystscoveringACADIAPharmaceuticals,theconsensusisthatbreakevenisnear.Theyexpectthecompanytopostafinallossin2023,beforeturningaprofitofUS$112min2024.Therefore,thecompanyisexpectedtobreakevenroughly12monthsfromnoworless.Atwhatratewillthecompanyhavetogrowinordertorealisetheconsensusestimatesforecastingbreakeveninunder12months?Usingalineofbestfit,wecalculatedanaverageannualgrowthrateof42%,whichsignalshighconfidencefromanalysts.Ifthisrateturnsouttobetooaggressive,thecompanymaybecomeprofitablemuchlaterthananalystspredict.
NasdaqGS:ACADEarningsPerShareGrowthMarch27th2024
We'renotgoingtogothroughcompany-specificdevelopmentsforACADIAPharmaceuticalsgiventhatthisisahigh-levelsummary,though,bearinmindthatgenerallybiotechs,dependingonthestageofproductdevelopment,haveirregularperiodsofcashflow.Thismeansthatahighgrowthrateisnotunusual,especiallyifthecompanyiscurrentlyinaninvestmentperiod.
Onethingwe'dliketopointoutisthatACADIAPharmaceuticalshasnodebtonitsbalancesheet,whichisquiteunusualforacash-burningbiotech,whichtypicallyhashighdebtrelativetoitsequity.Thecompanycurrentlyoperatespurelyoffitsshareholderfundingandhasnodebtobligation,reducingconcernsaroundrepaymentsandmakingitalessriskyinvestment.
NextSteps:
TherearetoomanyaspectsofACADIAPharmaceuticalstocoverinonebriefarticle,butthekeyfundamentalsforthecompanycanallbefoundinoneplace–ACADIAPharmaceuticals'companypageonSimplyWallSt.We'vealsocompiledalistofessentialfactorsyoushouldfurtherexamine:
Havefeedbackonthisarticle?Concernedaboutthecontent?Getintouchwithusdirectly.Alternatively,emaileditorial-team(at)simplywallst.com.
ThisarticlebySimplyWallStisgeneralinnature.Weprovidecommentarybasedonhistoricaldataandanalystforecastsonlyusinganunbiasedmethodologyandourarticlesarenotintendedtobefinancialadvice.Itdoesnotconstitutearecommendationtobuyorsellanystock,anddoesnottakeaccountofyourobjectives,oryourfinancialsituation.Weaimtobringyoulong-termfocusedanalysisdrivenbyfundamentaldata.Notethatouranalysismaynotfactorinthelatestprice-sensitivecompanyannouncementsorqualitativematerial.SimplyWallSthasnopositioninanystocksmentioned.